Company Encyclopedia
View More
name
BAO PHARMA-B
02659.HK
Shanghai Bao Pharmaceuticals Co., Ltd. is a clinical-stage biotechnology company uses synthetic biology technology to develop and deliver recombinant biologic drugs in Mainland China, Hong Kong, Macau, and Taiwan. Its products includes KJ017, a recombinant human hyaluronidase; KJ103, an recombinant immunoglobulin G (IgG)-degrading enzyme; SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP); BJ044, a recombinant ulinastatin developed through synthetic biology; BJ007, a SC administered ceftriaxone sodium for the treatment of bacterial infections; and KJ101, a recombinant human chymotrypsin developed through synthetic biology. The company also develops drug design platform, chassis cell engineering platform, and comprehensive bioprocessing platform.
1.338 T
02659.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BAO PHARMA creates another IPO myth, cornerstone investors earn 155 million daily

    BAO PHARMA was listed on the main board of the Hong Kong Stock Exchange, with an issue price of HKD 26.38 per share, and a closing price of HKD 63 per share on the first day, an increase of 138.32%, with a market capitalization of HKD 20.537 billion. Cornerstone investors earned HKD 155 million per day

    Stheadline·
    HK
    02659
    -0.94%
    Stheadline·
    HK
    02659
    -0.94%

    Top 10 HK Stock Gainers (12.11)

    MOBVISTA(01860) rose 14.76%, with a trading turnover 647.9 Million HKD, and a year-to-date rose 96.8%. XUANZHUBIO-B(02575) rose 14.16%, with a trading turnover 47.2 Million HKD, and a year-to-date rose 567.2%. BAO PHARMA-B(02659) rose 9.52%, with a trading turnover 144.5 Million HKD, and a year-to-date rose 161.6%.

    Top Gainers & Losers·
    HK
    01860
    -4.33%
    HK
    02575
    +7.17%
    HK
    02659
    -0.94%
    Top Gainers & Losers·
    HK
    01860
    -4.33%
    HK
    02575
    +7.17%
    HK
    02659
    -0.94%

    News: BAO PHARMA's first listing surged more than double at the opening

    Shanghai BAO PHARMA Co., Ltd. made its debut on the Hong Kong Stock Exchange, with the opening stock price soaring by 128%, and closing at a 125% increase at noon. The company issued 37.91 million shares at a price of HKD 26.38 per share, with the public offering oversubscribed by 3,525 times and the international placement oversubscribed by 5.6 times. The net fundraising amount is HKD 920 million, primarily used for the research and development and commercialization of core products, advancing existing product lines, optimizing technology platforms, enhancing production capacity, and general working capital

    BambooWorks·
    HK
    02659
    -0.94%
    BambooWorks·
    HK
    02659
    -0.94%

    The Hang Seng Index opened up 1 point, BAO PHARMA-B surged 129% on its debut, and CHI SILVER GP rose 7% | Hong Kong stock market opens

    The Hang Seng Index opened up 1 point, reporting at 25,435 points. BAO PHARMA-B listed on its first day, with its stock price rising 129.34% compared to the offering price. CHI SILVER GP's stock price increased by 7.46%. The three major U.S. stock indices showed mixed results, with the Dow Jones down 179 points, the S&P 500 down 6 points, and the Nasdaq up 30 points. JP Morgan's stock price fell sharply by 4.66%. Lixin Development sold a 50% stake in the Central CCB Tower, with JD.com as the buyer

    Stheadline·
    HK
    02659
    -0.94%
    HK
    00815
    +5.80%
    Stheadline·
    HK
    02659
    -0.94%
    HK
    00815
    +5.80%

    "New Shares" Biotechnology Stock BAO PHARMA's First Day of Subscription Over-Subscribed by 63 Times

    Biotechnology company BAO PHARMA is making its debut on the Hong Kong Stock Exchange, with a subscription oversubscription of 63 times. It is expected to raise a net amount of approximately HKD 922 million, of which 53.5% will be used for core product research and development and commercialization, 17.7% will be invested in other existing product lines, 8.4% will be used to optimize technology platforms and develop new drugs, 10.4% will be allocated to enhance production capacity, and the remaining 10% will be used for working capital and general purposes

    AASTOCKS·
    HK
    02659
    -0.94%
    AASTOCKS·
    HK
    02659
    -0.94%
    © 2025 Longbridge｜Disclaimer